Research progress on impact of neoadjuvant chemotherapy on the expression of ER, PR, HER-2, and Ki-67 in breast cancer
-
摘要: 目前乳腺癌已成为女性发病率最高的恶性肿瘤，新辅助化疗（neoadjuvant chemotherapy，NAC）后雌激素受体（estrogen receptor，ER）、孕激素受体（progesterone receptor，PR）和人表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）、Ki-67表达情况会有不同程度变化，这种变化机制是否会影响后续治疗方案的选择尚无定论。本文将就NAC对乳腺癌ER、PR、HER-2及Ki-67表达影响的研究进展进行综述。Abstract: Breast cancer has the highest incidence rate among all malignancies in women. The expression of estrogen receptors (ERs), progesterone receptors (PRs), human epidermal growth factor receptor-2 (HER-2), and Ki-67 changes to varying degrees after neoadjuvant chemotherapy. Whether the mechanism underlying these changes will affect the choice of subsequent treatment options remains unknown. We summarize the research progress of neoadjuvant chemotherapy on the expression of ER, PR, HER-2 and Ki-67 in breast cancer.
-
表 1 新辅助化疗后ER、PR、HER-2变化研究
-
[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. doi: 10.3322/caac.21338 [2] Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer:a systematic review and meta-analysis[J]. JAMA Oncol, 2016, 2(11):1477-1486. doi: 10.1001/jamaoncol.2016.1897 [3] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938):164-172. [4] Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression[J]. J Clin Oncol, 2012, 30(21):2601-2608. doi: 10.1200/JCO.2011.37.2482 [5] Dekker TJA, Smit V, Hooijer GKJ, et al. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer[J]. Ann Oncol, 2013, 24(4):931-937. doi: 10.1093/annonc/mds599 [6] Li S, Yang X, Zhang Y, et al. Assessment accuracy of core needle biopsy for hormone receptors in breast cancer:a meta-analysis[J]. Breast Cancer Res Treat, 2012, 135(2):325-334. doi: 10.1007/s10549-012-2063-z [7] Tamaki K, Sasano H, Ishida T, et al. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients[J]. Cancer Sci, 2010, 101(9):2074-2079. doi: 10.1111/j.1349-7006.2010.01630.x [8] Tacca O, Penaultllorca F, Abrial C, et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy[J]. Oncologist, 2007, 12(6):636-643. doi: 10.1634/theoncologist.12-6-636 [9] Van de Ven S, Smit V, Dekker TJA, et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer[J]. Cancer Treat Rev, 2011, 37(6):422-430. [10] Nie L, Wei Y, Zhang F, et al. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer[J]. Nat Commun, 2019, 10(1):1-15. doi: 10.1038/s41467-018-07882-8 [11] Wu Y, Li X, Lu L, et al. Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients:A retrospective study of 525 patients[J]. J Biomed Res, 2018, 32(3):191-197. [12] Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer:planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33):3744-3752. doi: 10.1200/JCO.2014.55.5730 [13] Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target:an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials[J]. Clin Cancer Res, 2005, 11(18):6598-6607. doi: 10.1158/1078-0432.CCR-05-0636 [14] Guarneri V, Dieci MV, Barbieri E, et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients[J]. Ann Oncol, 2013, 24(12):2990-2994. doi: 10.1093/annonc/mdt364 [15] Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2(HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors[J]. J Clin Oncol, 2012, 30(6):593-599. doi: 10.1200/JCO.2010.33.8889 [16] Ignatov T, Gorbunow F, Eggemann H, et al. Loss of HER2 after HER2-targeted treatment[J]. Breast Cancer Res Treat, 2019, 175(2):401-408. doi: 10.1007/s10549-019-05173-4 [17] Wang RX, Chen S, Jin X, et al. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer:loss of HER2 amplification and its impact on response and prognosis[J]. Breast Cancer Res Treat, 2017, 161(2):259-267. doi: 10.1007/s10549-016-4064-9 [18] Niikura N, Tomotaki A, Miyata H, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21755 patients from the Japanese breast cancer registry[J]. Ann Oncol, 2016, 27(3):480-487. doi: 10.1093/annonc/mdv611 [19] Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after antiHER2 chemotherapy in HER2-positive gastric cancer patients:results of the GASTric cancer HER2 reassessment study 3(GASTHER3)[J]. Gastric Cancer, 2019, 22(3):527-535. doi: 10.1007/s10120-018-0891-1 [20] Yoshida A, Hayashi N, Suzuki K, et al. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer[J]. J Surg Oncol, 2017, 116(8):1021-1028. doi: 10.1002/jso.24762 [21] Zhang N, Moran MS, Huo Q, et al. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy:a meta-analysis[J]. Cancer Invest, 2011, 29(9):594-598. doi: 10.3109/07357907.2011.621913 [22] Jin X, Jiang YZ, Chen S, et al. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients:a prospective observational study[J]. Oncotarget, 2015, 6(11):9600-9611. doi: 10.18632/oncotarget.3292 [23] Yang L, Zhong X, Pu T, et al. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy[J]. World J Surg Oncol, 2018, 16(1):1-9. doi: 10.1186/s12957-017-1299-9 [24] Guarneri V, Dieci MV, Barbieri E, et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients[J]. Ann Oncol, 2013, 24(12):2990-2994. doi: 10.1093/annonc/mdt364 [25] Parinyanitikul N, Lei X, Chavez-MacGregor M, et al. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes[J]. Clin Breast Cancer, 2015, 15(2):153-160. doi: 10.1016/j.clbc.2014.09.006 [26] Tural D, Karaca M, Zirtiloglu A, et al. Receptor discordances in locally advanced breast cancer after neoadjuvant chemotherapy and their effects on survival[J]. J Buon, 2019, 24(1):20-25. [27] Xie L, Li X, Wang Q, et al. Effects of core needle biopsy and subsequent neoadjuvant chemotherapy on molecular alterations and outcome in breast cancer[J]. Onco Targets Ther, 2018, 11:677-685. doi: 10.2147/OTT.S145715 [28] Li C, Fan H, Xiang Q, et al. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients:a systematic review and meta-analysis[J]. Breast Cancer Res Treat, 2019, 178(3):497-504. doi: 10.1007/s10549-019-05421-7 [29] Wu JY, Chen WG, Chen XS, et al. Long term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive to negative change of hormone receptor status following neoadjuvant chemotherapy[J]. Mol Clin Oncol, 2014, 2(6):997-1002. [30] Hirata T, Shimizu C, Yonemori K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer[J]. Brit J Cancer, 2009, 101(9):1529-1536. doi: 10.1038/sj.bjc.6605360 [31] Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer:an update[J]. Pathology, 2017, 49(2):166-171. doi: 10.1016/j.pathol.2016.11.006 [32] Petrelli F, Viale G, Cabiddu M, et al. Prognostic value of different cutoff levels of Ki-67 in breast cancer:a systematic review and metaanalysis of 64, 196 patients[J]. Breast Cancer Res Treat, 2015, 153(3):477-491. doi: 10.1007/s10549-015-3559-0 [33] Cabreragaleana P, Munozmontano W, Laramedina F, et al. Ki67 changes identify worse outcomes in residual breast cancer tumors after neoadjuvant chemotherapy[J]. Oncologist, 2018, 23(6):670-678. doi: 10.1634/theoncologist.2017-0396 -
点击查看大图
表(1)
计量
- 文章访问数: 264
- HTML全文浏览量: 142
- PDF下载量: 61
- 被引次数: 0
下载:
